Dr. Eisinger is a member of the executive management team at Myriad RBM, a leading multiplexed immunoassay testing laboratory providing comprehensive protein biomarker services for drug development within a CLIA certified laboratory. He directs sales, marketing, and business development in the therapeutic areas of immuno-oncology, oncology, autoimmune, metabolic, CNS and CVD applications. Dr. Eisinger joined Myriad RBM in 2006 when RBM acquired Multiplex Biosciences, a multiplex immunoassay development and manufacturing company he started and lead as President and CEO. He has over 22 years of industry leadership experience in various R&D, operational, and commercialization roles. Dr. Eisinger has B.S. in biochemistry from Cornell University and a PhD in stem cell molecular biology from the University of Vermont prior to completing post-doctoral training at Dartmouth Medical School.
Immunotherapy Showcase: Myriad RBM, Inc.
Myriad RBM, Inc. is a CLIA certified, multiplexed immunoassay testing laboratory.
Circulating IL-8: A New Response Predictor for Immunotherapies
Utilizing 2 immunoassay platforms validated to clinical laboratory standards for quantifying circulating proteins from immunotherapy clinical trial patients, select pharmacodynamic and prognostic biomarker findings will be presented including the discovery of IL-8 as a biomarker and therapy target.